- Grepafloxacin
- Grepafloxacin hydrochloride
- 161972-09-4Ethanone,1-(2,2-dimethyl-1,3-dioxolan-4-yl)-
- 161973-10-0Magnesium,bis[6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl-kO]-1H-benzimidazolato-kN3]-, (T-4)-
- 161975-39-91-Piperidinecarboxylicacid, 4-[[(methylsulfonyl)oxy]methyl]-, 1,1-dimethylethyl ester
- 161979-35-73,4-Oxazolidinedicarboxylic acid, 3-(1,1-dimethylethyl) ester, (S)-
- 16198-01-92H-1-Benzopyran-3,5,7-triol,2-[3,4-bis(acetyloxy)phenyl]-3,4-dihydro-, 3,5,7-triacetate, (2R,3S)-
- 161981-34-61-Octanol,7,7,8,8,8-pentafluoro-
- 161982-62-3Cyclo(L-homocysteinyl-N-methyl-L-phenylalanyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl),(1®1')-thioether with3-[(2-mercaptoacetyl)amino]-L-alanyl-L-lysyl-L-cysteinyl-L-lysinamide
- 1619-92-72-Propanamine,1,1,1,3,3,3-hexafluoro-
- 16200-52-51H-Pyrrole,3,4-diethyl-
- 16200-53-62,5-Methanopentalene-3a(1H)-carboxylicacid, hexahydro-
Hot Products
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
- 7631-86-9Silicon dioxide
- 302-79-4Tretinoin
- 77-92-9Citric acid
|
Basic Information |
|
Post buying leads |
|
Suppliers |
| Name |
Grepafloxacin hydrochloride |
EINECS | N/A |
| CAS No. | 161967-81-3 | Density | N/A |
| PSA | 74.57000 | LogP | 3.47600 |
| Solubility | N/A | Melting Point |
N/A |
| Formula | C19H22FN3O3.HCl | Boiling Point | 626.7 °C at 760 mmHg |
| Molecular Weight | 395.86 | Flash Point | 332.8 °C |
| Transport Information | N/A | Appearance | N/A |
| Safety | Risk Codes | N/A | |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
3-Quinolinecarboxylicacid,1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-,monohydrochloride (9CI);3-Quinolinecarboxylic acid,1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-,monohydrochloride, (?à)-;Grepafloxacin hydrochloride;OPC 17116;Raxar;Vaxar;dl-Grepafloxacinhydrochloride; |
Grepafloxacin hydrochloride Specification
The Grepafloxacin hydrochloride with the CAS number 161967-81-3 is also called 3-Quinolinecarboxylicacid,1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-,hydrochloride (1:1). The IUPAC name is 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid hydrochloride. Its molecular formula is C19H22FN3O3.HCl.
The properties of the chemical are: (1)ACD/LogP: 1.61; (2)# of Rule of 5 Violations: 0; (3)#H bond acceptors: 6; (4)#H bond donors: 2; (5)#Freely Rotating Bonds: 3; (6)Polar Surface Area: 53.09 Å2; (7)Flash Point: 332.8 °C; (8)Enthalpy of Vaporization: 97.51 kJ/mol; (9)Boiling Point: 626.7 °C at 760 mmHg; (10)Vapour Pressure: 1.43×10-16 mmHg at 25°C.
Uses: This chemical can react with methanol to prepare 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methyl ester. This reaction needs reagent SOCl2 at heating condition. The reaction time is 4.0 hours. The yield is 77%.
You can still convert the following datas into molecular structure:
(1)SMILES: Cl.O=C(O)\C2=C\N(c1cc(c(F)c(c1C2=O)C)N3CC(NCC3)C)C4CC4
(2)InChI: InChI=1/C19H22FN3O3.ClH/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12;/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26);1H
(3)InChIKey: IEPMBYOIQGCVHO-UHFFFAOYAR
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| monkey | LD50 | intravenous | > 100mg/kg (100mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: NAUSEA OR VOMITING | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995. |
| monkey | LD50 | oral | > 2gm/kg (2000mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995. |
| mouse | LD50 | intravenous | 69200ug/kg (69.2mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995. |
| mouse | LD50 | oral | 3900mg/kg (3900mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: TREMOR | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995. |
| mouse | LD50 | subcutaneous | > 2gm/kg (2000mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995. |
| rat | LD50 | intravenous | 152mg/kg (152mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995. |
| rat | LD50 | oral | 3029mg/kg (3029mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995. |
| rat | LD50 | subcutaneous | > 2gm/kg (2000mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 464, 1995. |
What can I do for you?
Get Best Price
